Elevated Blood PressureNCT02513823
Effectiveness of Vitamin D Supplementation
A study testing 2,000 International Units (IU)of vitamin D3 in people with Elevated Blood Pressure and Endothelial Dysfunction, run by Texas Woman's University at 1 site in United States.
Trial summary
This pilot study will examine the effectiveness of vitamin D supplementation on reducing blood pressure and improving endothelial function. Premenopausal African American women will be recruited. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Elevated Blood Pressure, Endothelial Dysfunction
- What is being tested?
- 2,000 International Units (IU)of vitamin D3
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Dec 2015to 14 Oct 2016
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy pre-menomausal African American women
Who cannot join
- History of elevated blood pressure >140/90 mm Hg
- Pregnant or planning to become pregnant in the next three months
- Lactating
- Known Crohn's
- Inflammatory bowel disease
- Previous bowel resections
Show all 9Show fewer
- Bariatric surgeries, or psoriasis
- Artificial or long fingernails they do not want to cut for testing
- Regularly taking medications that might affect endothelial function such as anti-inflammatory medications, statins, anti-hypertensive medication, daily aspirin, non-SSRI psychotropic medication, and dietary supplements including vitamin D supplements
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effectiveness of Vitamin D Supplementation on Reducing Blood Pressure and Improving Endothelial Function of Pre-menopausal African American Women
This pilot study will examine the effectiveness of vitamin D supplementation on reducing blood pressure and improving endothelial function. Premenopausal African American women will be recruited. Participants will be instructed to record food intake for three days to estimate usual dietary intake at baseline and at the 10th week. At the baseline clinic visit a 10 week supply of vitamin D3 supplements (2,000 IU/day; Nature Made ®) will be given to participants and log sheets provided to record supplement intake. To answer the primary research questions, within subjects repeated measures analysis of variance (ANOVA) tests will be conducted to test if any differences in blood pressure, serum 25(OH)D concentrations, and RHI are statistically different after 10 weeks of supplementation with 2,000 IU/d of vitamin D. Exploratory multivariate linear regression models will be constructed to determine relationships between vitamin D status and vascular function parameters (blood pressure, RHI) before and after adjustment for age and BMI.
Read the detailed description
This pilot study will examine the effectiveness of vitamin D supplementation on reducing blood pressure and improving endothelial function. If results of the pilot study are favorable, findings will be used to design a possibly larger study to confirm results. Premenopausal African American women (n = 40) will be recruited. All participant study visits will be held at the Houston Methodist Internal Medicine Clinic or at the TWU Nutrition Laboratory. African American women will be recruited who are not taking hypertensive medications, have average blood pressure measurements < 140/90 mmHg, are not pregnant or planning on becoming pregnant in the next three months, or who are not lactating.
Enrollment Visit The day prior to the enrollment visit potential subjects will fast overnight and refrain from consuming any caffeinated products, vitamins, or medications that may affect vascular tone and refrain from smoking. the investigators will explain the 10 week study design and obtain participant consent. Testing will be performed in the morning with start times between 8 and 10:00 a.m. In a quiet and temperature-controlled room (72° to 75° F), initial systolic and diastolic blood pressure measurements following 5 minutes of seated rest following the American Heart Association Blood Pressure Guidelines. The arm will be supported at heart level and neither participant nor observer will talk during the measurements. Three successive measurements will be collected with an automated oscillometric sphygmomanometer and the average of the last two measurements will be calculated. Any individual with an average blood pressure > 140/90 mmHg will be referred to their personal physician for follow up.
Consented participants with blood pressure readings <140/90 mmHg will be instructed to consume their usual diet for the next week and to complete a three-day diet record of two week days and one weekend. Instructions on how to record the dietary diary will be given. Food records will be used to estimate usual dietary intake for the baseline and 10 week time points. An appointment will be scheduled for the participant to return with completed food records to begin the intervention study. At the baseline clinic visit a 10 week supply of vitamin D3 supplements (2,000 IU/day; all the same lot; Nature Made ®) will be given to participants and log sheets provided to record supplement intake. In addition, participants will be instructed to avoid traveling to sunny locations for 10 weeks.
Baseline and 10 week clinic visits
Nutrient intake:
Three-day diet records will be collected during the baseline and 10 week clinic visits. Food records will be analyzed at TWU utilizing the University of Minnesota 2015 Nutrient Data System for Research. Total energy intake; percent calories from fat, protein and carbohydrates; and intake of vitamins A, C, D, E and beta carotene will be estimated from food records.
Blood pressure measurements:
Participants will fast overnight and refrain from consuming any caffeinated products, vitamins, medications that may affect vascular tone, or smoking. Testing will be performed in the morning with start times between 8 and 10:00 a.m. In a quiet and temperature-controlled room (72° to 75° F), initial systolic and diastolic blood pressure measurements will be taken following 5 minutes of seated rest following the American Heart Association Blood Pressure Guidelines. The arm will be supported at heart level and neither participant nor observer will talk during the measurements. Three successive measurements will be collected with an automated oscillometric sphygmomanometer and the average of the last two measurements will be calculated.
Body fat and adiposity measures:
Anthropometric and body fat distribution assessments will be performed. Height and weight will be measured. Percent body fat will be determined by bioelectric impedance (Tanita BF-350). Body mass index (BMI) will be calculated as weight in kilograms (kg) divided by height squared (m2).
Endothelial pulse amplitude measurements:
Pulse amplitude tonometry (PAT) will be measured with the EndoPAT 2000 (Itamar Medical Ltd) which records digital pulse wave amplitude (PWA) using fingertip plethysmography (16). The Endo-PAT finger probe consists of a thimble-shaped sensor cap that imparts a uniform pressure field and exhibits a clamp-like effect on the entire surface of the distal phalanx and measured pulsatile volume changes. PWA is measured continuously during three phases: a quiet baseline period, 5-minute forearm occlusion, and reactive hyperemia following cuff release. Occlusion of the brachial artery is performed on the non-dominant upper arm. The continuous monitoring of blood volume reaching the finger tips allows the hyperemic response to be quantified as a ratio, comparing PWA from pre to post occlusion. A reactive hyperemia index (RHI) measures nitric-oxide dependent changes in vascular tone. The recordings from the non-occluded arm serve as a control for changes in overall physiological state. The Endo-PAT RHI index is defined as the ratio of the average PWS during the 1 minute period beginning after exactly 90 second to reactive hyperemia compared with the average pulse amplitude during the 210 second pre-occlusion baseline period. Endothelial dysfunction is classified as a RHI < 1.67 with average normal endothelial RHI values ranging between 1.7 and 2.0.
Vitamin D measurements:
Blood will be drawn by Houston Methodist Hospital laboratory for measurement of serum 25(OH)D concentrations by chemiluminescence immunoassay( Abbott Architect). Vitamin D deficiency will be defined as serum 25(OH)D levels less than 20 ng/mL (50 nmol/L) and vitamin D insufficiency as 21 to 29 ng/mL (50 to 80 nmol/L).
Statistical analyses:
Descriptive statistics, including means and standard deviations for continuous variables and frequencies and percentages for categorical variables, will be calculated for study variables. Age, BMI, blood pressure, serum 25(OH)D concentration, and RHI will be treated as continuous variables. Prior to conducting primary analyses, exploratory and preliminary analyses will be conducted to test the statistical assumptions of planned analyses. Specifically, these assumptions include normality, homogeneity of variance, equivalent group size, and data that is missing by random. In the event that any of these assumptions have been violated, the data will either be transformed to meet the parametric assumptions of planned analyses or non-parametric equivalencies will be conducted as an alternative. In addition, correlation analyses, including Pearson's product moment correlations for normally distributed variables and Spearman's rho for non-normally distributed variables, will be conducted to examine the variables for potentially collinear relationships, which may impact primary analyses.
To answer the primary research questions, within subjects repeated measures analysis of variance (ANOVA) tests will be conducted to test if differences in blood pressure, serum 25(OH)D concentrations, and RHI are statistically different after 10 weeks of supplementation with 2,000 IU/d of vitamin D. Furthermore, exploratory multivariate linear regression models will be constructed to determine relationships between vitamin D status and vascular function parameters (blood pressure, RHI) before and after adjustment for age and BMI. All statistical analyses will be performed using Statistical analyses SPSS (version 19; SPSS IBM) and p < 0.05 will be used to determine statistical significance.
A priori power analyses was conducted using G*Power (v. 3.0.10) in order to determine an adequate sample size to detect statistical significance if significance in fact exists. In order to obtain a desired level of power at .80, estimating a moderate effect size (.25) and an alpha level of .05, a total of 22 participants will be needed to to ensure a statistically significant increase in serum 25(OH)D concentrations. Accounting for attrition of approximately 15%, a total of 25 participants will be recruited. Repeated measures-ANOVAs will be utilized to detect significant changes across the following outcome variables: serum 25(OH)D, blood pressure, and RHI. As such, a total of 25 participants should be sufficient to detect significance if significance in fact exists across all planned analyses.
- Conditions
- Elevated Blood Pressure, Endothelial Dysfunction
- Being tested
- 2,000 International Units (IU)of vitamin D3
- Keywords
- blood pressure, vitamin D
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
2,000 International Units (IU)of vitamin D3Dietary supplement
2,000 IU vitamin D taken daily for 10 weeks
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | 2,000 IU of vitamin D given to African American women for 10 weeks Receives: Dietary Supplement: 2,000 International Units (IU)of vitamin D3 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effectiveness of Vitamin D Supplementation on Reducing Blood Pressure
Changes in systolic and diastolic blood pressure will be measured at baseline and following vitamin D supplementation for 10 weeks in African American healthy pre-menopausal women
Measured: Baseline and 10 weeks
Secondary outcomes (1)
Effectiveness of Vitamin d Supplementation on Improving Endothelial Function
Changes of endothelial function at baseline and following 10 weeks of vitamin D supplementation as measured by pulse amplitude tonometry (PAT) fingertip plethysmography. Endothelial dysfunction was classified as a Reactive Hyperemic Index (RHI) of < 1.67 . RHI scale typical ranges from 1.0 to 3.0.
Measured: Baseline and 10 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2015 (estimated)
- Study start1 Dec 2015
- Primary completion1 Aug 2016
- Study completion14 Oct 2016
Why it stopped: Reached power analysis goal and funds depleted
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Elevated Blood PressureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- Texas Woman's University
- Sponsor type
- University, hospital or other
- Collaborators
- The Methodist Hospital Research Institute
- Responsible party
- Principal investigator, Carolyn Moore, Texas Woman's University
- Investigators
- Carolyn Moore, PHD, RD, LD, Principal investigator, Methodist Hosptial
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02513823
- Sponsor's protocol ID
- 11089
- Status last verified
- Oct 2019
- First submitted
- 30 Jul 2015
- Last updated
- 4 Oct 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Vitamin D Supplementation on Reducing Blood Pressure and Improving Endothelial Function of Pre-menopausal African American Women
- ClinicalTrials.gov ID
- NCT02513823
- Acronym / sponsor ID
- 11089
- Conditions
- Elevated Blood Pressure, Endothelial Dysfunction
- Keywords
- blood pressure, vitamin D
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Reached power analysis goal and funds depleted
- Enrolment
- 27 participants (actual)
- Lead sponsor
- Texas Woman's UniversityUniversity, hospital or other
- Collaborators
- The Methodist Hospital Research Institute
- Study start
- 1 Dec 2015 (actual)
- Primary completion
- 1 Aug 2016 (actual)
- Study completion
- 14 Oct 2016 (actual)
- First posted
- 3 Aug 2015 (estimated)
- Results
- Posted 4 Oct 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This pilot study will examine the effectiveness of vitamin D supplementation on reducing blood pressure and improving endothelial function. Premenopausal African American women will be recruited. Participants will be instructed to record food intake for three days to estimate usual dietary intake at baseline and at the 10th week. At the baseline clinic visit a 10 week supply of vitamin D3 supplements (2,000 IU/day; Nature Made ®) will be given to participants and log sheets provided to record supplement intake. To answer the primary research questions, within subjects repeated measures analysis of variance (ANOVA) tests will be conducted to test if any differences in blood pressure, serum 25(OH)D concentrations, and RHI are statistically different after 10 weeks of supplementation with 2,000 IU/d of vitamin D. Exploratory multivariate linear regression models will be constructed to determine relationships between vitamin D status and vascular function parameters (blood pressure, RHI) before and after adjustment for age and BMI.
Detailed description
This pilot study will examine the effectiveness of vitamin D supplementation on reducing blood pressure and improving endothelial function. If results of the pilot study are favorable, findings will be used to design a possibly larger study to confirm results. Premenopausal African American women (n = 40) will be recruited. All participant study visits will be held at the Houston Methodist Internal Medicine Clinic or at the TWU Nutrition Laboratory. African American women will be recruited who are not taking hypertensive medications, have average blood pressure measurements < 140/90 mmHg, are not pregnant or planning on becoming pregnant in the next three months, or who are not lactating.
Enrollment Visit The day prior to the enrollment visit potential subjects will fast overnight and refrain from consuming any caffeinated products, vitamins, or medications that may affect vascular tone and refrain from smoking. the investigators will explain the 10 week study design and obtain participant consent. Testing will be performed in the morning with start times between 8 and 10:00 a.m. In a quiet and temperature-controlled room (72° to 75° F), initial systolic and diastolic blood pressure measurements following 5 minutes of seated rest following the American Heart Association Blood Pressure Guidelines. The arm will be supported at heart level and neither participant nor observer will talk during the measurements. Three successive measurements will be collected with an automated oscillometric sphygmomanometer and the average of the last two measurements will be calculated. Any individual with an average blood pressure > 140/90 mmHg will be referred to their personal physician for follow up.
Consented participants with blood pressure readings <140/90 mmHg will be instructed to consume their usual diet for the next week and to complete a three-day diet record of two week days and one weekend. Instructions on how to record the dietary diary will be given. Food records will be used to estimate usual dietary intake for the baseline and 10 week time points. An appointment will be scheduled for the participant to return with completed food records to begin the intervention study. At the baseline clinic visit a 10 week supply of vitamin D3 supplements (2,000 IU/day; all the same lot; Nature Made ®) will be given to participants and log sheets provided to record supplement intake. In addition, participants will be instructed to avoid traveling to sunny locations for 10 weeks.
Baseline and 10 week clinic visits
Nutrient intake:
Three-day diet records will be collected during the baseline and 10 week clinic visits. Food records will be analyzed at TWU utilizing the University of Minnesota 2015 Nutrient Data System for Research. Total energy intake; percent calories from fat, protein and carbohydrates; and intake of vitamins A, C, D, E and beta carotene will be estimated from food records.
Blood pressure measurements:
Participants will fast overnight and refrain from consuming any caffeinated products, vitamins, medications that may affect vascular tone, or smoking. Testing will be performed in the morning with start times between 8 and 10:00 a.m. In a quiet and temperature-controlled room (72° to 75° F), initial systolic and diastolic blood pressure measurements will be taken following 5 minutes of seated rest following the American Heart Association Blood Pressure Guidelines. The arm will be supported at heart level and neither participant nor observer will talk during the measurements. Three successive measurements will be collected with an automated oscillometric sphygmomanometer and the average of the last two measurements will be calculated.
Body fat and adiposity measures:
Anthropometric and body fat distribution assessments will be performed. Height and weight will be measured. Percent body fat will be determined by bioelectric impedance (Tanita BF-350). Body mass index (BMI) will be calculated as weight in kilograms (kg) divided by height squared (m2).
Endothelial pulse amplitude measurements:
Pulse amplitude tonometry (PAT) will be measured with the EndoPAT 2000 (Itamar Medical Ltd) which records digital pulse wave amplitude (PWA) using fingertip plethysmography (16). The Endo-PAT finger probe consists of a thimble-shaped sensor cap that imparts a uniform pressure field and exhibits a clamp-like effect on the entire surface of the distal phalanx and measured pulsatile volume changes. PWA is measured continuously during three phases: a quiet baseline period, 5-minute forearm occlusion, and reactive hyperemia following cuff release. Occlusion of the brachial artery is performed on the non-dominant upper arm. The continuous monitoring of blood volume reaching the finger tips allows the hyperemic response to be quantified as a ratio, comparing PWA from pre to post occlusion. A reactive hyperemia index (RHI) measures nitric-oxide dependent changes in vascular tone. The recordings from the non-occluded arm serve as a control for changes in overall physiological state. The Endo-PAT RHI index is defined as the ratio of the average PWS during the 1 minute period beginning after exactly 90 second to reactive hyperemia compared with the average pulse amplitude during the 210 second pre-occlusion baseline period. Endothelial dysfunction is classified as a RHI < 1.67 with average normal endothelial RHI values ranging between 1.7 and 2.0.
Vitamin D measurements:
Blood will be drawn by Houston Methodist Hospital laboratory for measurement of serum 25(OH)D concentrations by chemiluminescence immunoassay( Abbott Architect). Vitamin D deficiency will be defined as serum 25(OH)D levels less than 20 ng/mL (50 nmol/L) and vitamin D insufficiency as 21 to 29 ng/mL (50 to 80 nmol/L).
Statistical analyses:
Descriptive statistics, including means and standard deviations for continuous variables and frequencies and percentages for categorical variables, will be calculated for study variables. Age, BMI, blood pressure, serum 25(OH)D concentration, and RHI will be treated as continuous variables. Prior to conducting primary analyses, exploratory and preliminary analyses will be conducted to test the statistical assumptions of planned analyses. Specifically, these assumptions include normality, homogeneity of variance, equivalent group size, and data that is missing by random. In the event that any of these assumptions have been violated, the data will either be transformed to meet the parametric assumptions of planned analyses or non-parametric equivalencies will be conducted as an alternative. In addition, correlation analyses, including Pearson's product moment correlations for normally distributed variables and Spearman's rho for non-normally distributed variables, will be conducted to examine the variables for potentially collinear relationships, which may impact primary analyses.
To answer the primary research questions, within subjects repeated measures analysis of variance (ANOVA) tests will be conducted to test if differences in blood pressure, serum 25(OH)D concentrations, and RHI are statistically different after 10 weeks of supplementation with 2,000 IU/d of vitamin D. Furthermore, exploratory multivariate linear regression models will be constructed to determine relationships between vitamin D status and vascular function parameters (blood pressure, RHI) before and after adjustment for age and BMI. All statistical analyses will be performed using Statistical analyses SPSS (version 19; SPSS IBM) and p < 0.05 will be used to determine statistical significance.
A priori power analyses was conducted using G*Power (v. 3.0.10) in order to determine an adequate sample size to detect statistical significance if significance in fact exists. In order to obtain a desired level of power at .80, estimating a moderate effect size (.25) and an alpha level of .05, a total of 22 participants will be needed to to ensure a statistically significant increase in serum 25(OH)D concentrations. Accounting for attrition of approximately 15%, a total of 25 participants will be recruited. Repeated measures-ANOVAs will be utilized to detect significant changes across the following outcome variables: serum 25(OH)D, blood pressure, and RHI. As such, a total of 25 participants should be sufficient to detect significance if significance in fact exists across all planned analyses.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Dietary Supplement: 2,000 International Units (IU)of vitamin D32,000 IU of vitamin D given to African American women for 10 weeks |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Healthy pre-menomausal African American women
Key exclusion criteria (9 listed)
- History of elevated blood pressure >140/90 mm Hg
- Pregnant or planning to become pregnant in the next three months
- Lactating
- Known Crohn's
- Inflammatory bowel disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 2,000 International Units (IU)of vitamin D32,000 IU vitamin D taken daily for 10 weeks | Dietary supplement | Intervention |
Primary outcome
Effectiveness of Vitamin D Supplementation on Reducing Blood Pressure
Time frame: Baseline and 10 weeks
Changes in systolic and diastolic blood pressure will be measured at baseline and following vitamin D supplementation for 10 weeks in African American healthy pre-menopausal women
1 secondary outcome
Effectiveness of Vitamin d Supplementation on Improving Endothelial Function
Time frame: Baseline and 10 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Oct 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Elevated Blood Pressure
Not yet recruiting
PAUL® Glaucoma Implant Safety and Effectiveness Study
Refractory Glaucoma
RecruitingObservational study
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
Asthma Bronchial
RecruitingObservational study
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Intracerebral Hemorrhage, Stroke
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Recruiting
Dry Weight Reduction Intervention Via Extra Ultrafiltration
Fluid Accumulation, Blood Pressure Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carolyn Moore, PHD, RD, LD principal investigator
Methodist Hosptial
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 2,000 International Units (IU)of vitamin D3 in people with Elevated Blood Pressure and Endothelial Dysfunction, run by Texas Woman's University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 4 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 4 Oct 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effectiveness of Vitamin D Supplementation on Reducing Blood Pressure (time frame: Baseline and 10 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Oct 2019.